New drug combo aims to shrink metastatic kidney tumors
NCT ID NCT01038778
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 31 times
Summary
This study tests whether adding entinostat to high-dose aldesleukin (interleukin-2) can help shrink tumors in people with metastatic kidney cancer. About 47 adults with clear cell renal cell carcinoma that has spread will receive both drugs. The goal is to find the safest dose and see how many patients respond to treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
entinostat and aldesleukin (interleukin-2)
What this could lead to
If it works, this combination could offer a new treatment option for people with advanced kidney cancer that has spread.
What could go wrong
This is an early-phase trial with only 47 participants, so results may not apply to everyone. The drugs can cause serious side effects, and the combination may not work better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.